Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor
- Nat Biotechnol. 2024 Dec 11. doi: 10.1038/s41587-024-02503-w.
- 1. Insilico Medicine US, Inc., Boston, MA, USA.
- 2. Insilico Medicine Shanghai, Ltd., Shanghai, China.
- 3. Insilico Medicine Hong Kong, Ltd., Hong Kong, China.
- 4. Insilico Medicine AI, Ltd., Abu Dhabi, UAE.
- 5. Insilico Medicine US, Inc., New York, NY, USA.
- 6. Insilico Medicine Canada, Inc., Montréal, Québec, Canada.
- 7. Insilico Medicine US, Inc., Boston, MA, USA. [email protected].
- 8. Insilico Medicine Shanghai, Ltd., Shanghai, China. [email protected].
- 9. Insilico Medicine Hong Kong, Ltd., Hong Kong, China. [email protected].
- 10. Insilico Medicine US, Inc., New York, NY, USA. [email protected].
Hypoxia-inducible factor prolyl hydroxylase (PHD) inhibitors have been approved for treating renal anemia yet have failed clinical testing for inflammatory bowel disease because of a lack of efficacy. Here we used a multimodel multimodal generative artificial intelligence platform to design an orally gut-restricted selective PHD1 and PHD2 inhibitor that exhibits favorable safety and pharmacokinetic profiles in preclinical studies. ISM012-042 restores intestinal barrier function and alleviates gut inflammation in multiple experimental colitis models.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-
target: HIF/HIF Prolyl-HydroxylaseResearch Areas: Inflammation/Immunology